Dr. Ahmad Tarhini on Ipilimumab vs Interferon-?2b for Resected High-Risk Melanoma

Source:  Cancer Network, July 2019

Cancer Network spoke with Ahmad Tarhini, MD, PhD, a medical oncologist with at Emory Winship Cancer Institute, about a phase III study of adjuvant ipilimumab versus high-dose interferon-a2b for treating resected high-risk melanoma. The results of the trial were presented at ASCO 2019.